Use of manzamine compounds in anti-cancer therapeutic regimens
US8691801B2 · kind B2 · utility
2Cited by
4References
1Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 17, 2012 |
| Grant date | Apr 8, 2014 |
| Priority date | — |
| Expiry date | Jul 17, 2032 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Manzamine compounds have been discovered to decrease cell dissociation and cell migration associated with the metastatic potential of cancer cells and a restoration of cancer cell susceptibility to agents, such as TRAIL, which can induce apoptosis. Specifically, Manzamine A has a formerly unrecognized utility in both blocking tumor cell invasion and tumor metastasis as well in restoring cancer cell susceptibility to standard chemotherapeutic agents which induce apoptosis and, therefore, has utility in treating cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.